Cytovance Biologics and PolyPeptide have announced a partnership that combines Cytovance’s expertise in microbial and mammalian expression, process development and cGMP manufacturing with PolyPeptide’s capabilities in complex peptide development and manufacturing.
Axel Schleyer, CCO of Cytovance Biologics: “Cytovance has been supporting the development and scale-up of microbial and mammalian-expressed biologics for two decades. Combining our strengths with PolyPeptide’s is exactly what our customers and the industry need to support the rapidly advancing market demand.”
Trishul Shah, PolyPeptide Director of Business Development: “With a track record of over 1,000 therapeutic peptides manufactured, PolyPeptide offers deep peptide development and synthesis capabilities. The collaboration gives customers access to complementary technology portfolios to drive their innovative drug development projects.”
Also Read: A2 Biotherapeutics Secures $80M in Series C for Precision Cell Therapies
The two companies have partnered before on specific customer projects. The new collaboration broadens the partnership to the benefit of drug developers looking for additional capacity, fast ramp-up, and increased efficiency, helping to propel new peptide products to the clinic and the market.
PolyPeptide Group AG with its consolidated subsidiaries is a focused Contract Development & Manufacturing Organization (CDMO) which specializes in the development and manufacturing of synthetic peptides and oligonucleotides used as active pharmaceutical ingredients (API) or intermediates in therapeutic products. It also produces a range of generic peptides and peptides used in cosmetics. The Group mainly serves pharmaceutical and biotech companies.
Cytovance Biologics! Born from a decades-long history in drug development, we believe in creating a healthier world where every biologic’s path to commercialization is advanced by a CDMO partner that delivers ingenuity end-to-end. Whether your large molecule product needs the flexibility of a customized approach or the efficiency of a predetermined platform process, Team Cytovance has the deep expertise in microbial and mammalian expression systems to support your scale-up at every stage.
SOURCE: Businesswire